<DOC>
	<DOC>NCT00549133</DOC>
	<brief_summary>To show that Irbesartan improves endothelial dysfunction and the procoagulant state which are thought to be the possible mechanisms, inducing a generalized vasculopathy associated with microalbuminuria and vascular events in type II diabetic hypertensive patients</brief_summary>
	<brief_title>Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<criteria>non insulin dependent type II manifest diabetes with glycosilated HbA1c levels over %6.58 mild to moderate hypertension stage I and stage II according to ESCESH 2003 (140180 mmHg) congestive heart failure azotemia insulin dependent diabetes liver insufficiency pregnancy cancer The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Microalbuminaria in hypertensive patients with type II diabetes mellitus</keyword>
</DOC>